Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial-

Trial Profile

Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial-

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Acquired immunodeficiency syndrome; Haematological malignancies; HIV infections; Immunocompromised infections; Renal failure
  • Focus Therapeutic Use
  • Acronyms CPI study
  • Most Recent Events

    • 22 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top